50,466 results on '"INTERLEUKIN-2"'
Search Results
2. Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
3. Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma
4. Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL (LuminICE-203)
5. A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer
6. Phase II Clinical Trial of Interleukin-2 in AD
7. Low-dose IL-2 in Established T1D - The "PROREG" Study
8. Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
9. LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
10. Diabetes Islet Preservation Immune Treatment (DIPIT)
11. Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer
12. Low-dose Interleukin-2 in Women With Unexplained Miscarriages (FaCIL-2)
13. Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL
14. CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma
15. IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
16. T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer
17. IL2 Imaging in Metastatic Melanoma
18. A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors
19. Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma
20. A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020
21. Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma
22. Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma
23. Low Dose IL-2 for the Treatment of Crohn's Disease
24. Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients (INTACT/MeRCI)
25. Extracorporeal Photopheresis and Low Dose Aldesleukin in Treating Patients With Steroid Refractory Chronic Graft-Versus-Host Disease
26. Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus
27. Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer
28. Regulatory T cells in skin mediate immune privilege of the hair follicle stem cell niche
29. A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1)
30. Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
31. Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
32. "Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
33. Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors
34. Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies
35. Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
36. Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors (TAL-T)
37. TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC
38. Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma (DiTuSarc)
39. Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye
40. Vaccine Therapy in Treating Patients With Metastatic Cancer
41. Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
42. Quadruple Immunotherapy for Neuroblastoma
43. CIML NK Cells With Venetoclax for AML
44. Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma
45. Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
46. Low-dose Recombinant Human IL-2 for the Treatment of Relapsing Polychondritis
47. ACTolog in Patients With Solid Cancers (ACTolog)
48. Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts
49. The Maintenance Treatment of "ITIVA" in AML Patients
50. The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.